Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Shandong Wit Dyne Health Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥23.87 |
52 Week High | CN¥37.08 |
52 Week Low | CN¥23.80 |
Beta | 0.056 |
11 Month Change | -12.60% |
3 Month Change | -26.12% |
1 Year Change | -24.39% |
33 Year Change | -15.14% |
5 Year Change | 3.69% |
Change since IPO | 187.52% |
Recent News & Updates
There's No Escaping Shandong Wit Dyne Health Co.,Ltd.'s (SZSE:000915) Muted Earnings
Sep 14Shandong Wit Dyne HealthLtd (SZSE:000915) Is Increasing Its Dividend To CN¥2.00
May 12Shareholder Returns
000915 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -7.4% | -2.9% | -2.1% |
1Y | -24.4% | -17.4% | -21.1% |
Return vs Industry: 000915 underperformed the CN Pharmaceuticals industry which returned -15.2% over the past year.
Return vs Market: 000915 underperformed the CN Market which returned -20.6% over the past year.
Price Volatility
000915 volatility | |
---|---|
000915 Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 5.4% |
10% most volatile stocks in CN Market | 8.6% |
10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 000915's share price has been volatile over the past 3 months.
Volatility Over Time: 000915's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 1,763 | Jie Yang | www.sd-wit.com |
Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets.
Shandong Wit Dyne Health Co.,Ltd. Fundamentals Summary
000915 fundamental statistics | |
---|---|
Market cap | CN¥5.59b |
Earnings (TTM) | CN¥595.29m |
Revenue (TTM) | CN¥2.49b |
9.4x
P/E Ratio2.3x
P/S RatioIs 000915 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
000915 income statement (TTM) | |
---|---|
Revenue | CN¥2.49b |
Cost of Revenue | CN¥342.31m |
Gross Profit | CN¥2.14b |
Other Expenses | CN¥1.55b |
Earnings | CN¥595.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.54 |
Gross Margin | 86.23% |
Net Profit Margin | 23.95% |
Debt/Equity Ratio | 0% |
How did 000915 perform over the long term?
See historical performance and comparison